Search research articles
Contact Us
Filters
Showing results (51-60 of 129) with videos related to
Page
of 13
Sort By:
Medicine and Science in Sports and Exercise
|
November 5, 2011
Isomaltulose improves glycemia and maintains run performance in type 1 diabetes
Richard Michael Bracken, Rhydian Page, Benjamin Gray, et al.
Kidney International Reports
|
December 19, 2022
Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: <i>post hoc</i> Analysis of the SUSTAIN and PIONEER Programs
David Z I Cherney, Samy Hadjadj, Jack Lawson, et al.
Cardiovascular Diabetology
|
August 24, 2023
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Peter Rossing, Stephen C Bain, Heidrun Bosch-Traberg, et al.
Journal of Sports Sciences
|
December 15, 2010
A combined insulin reduction and carbohydrate feeding strategy 30 min before running best preserves blood glucose concentration after exercise through improved fuel oxidation in type 1 diabetes mellitus
Daniel J West, Jeffrey W Stephens, Stephen C Bain, et al.
Diabetes, Obesity & Metabolism
|
May 4, 2023
Impact of severe hypoglycaemia requiring hospitalization on mortality in people with type 1 diabetes: A national retrospective observational cohort study
Othmar Moser, James Rafferty, Max L Eckstein, et al.
The New England Journal of Medicine
|
June 25, 2023
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
Julio Rosenstock, Stephen C Bain, Amoolya Gowda, et al.
The Lancet. Diabetes & Endocrinology
|
March 28, 2017
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Vanita R Aroda, Stephen C Bain, Bertrand Cariou, et al.
Frontiers in Public Health
|
January 26, 2021
Improved Nocturnal Glycaemia and Reduced Insulin Use Following Clinical Exercise Trial Participation in Individuals With Type 1 Diabetes
Olivia McCarthy, Rachel Deere, Max L Eckstein, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
September 24, 2021
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population-based observational retrospective cohort study
Kamlesh Khunti, Christin L Hertz, Lise Lotte N Husemoen, et al.
Cardiovascular Diabetology
|
June 7, 2019
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
Lawrence A Leiter, Stephen C Bain, Irene Hramiak, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 129) with videos related to
Sort By:
Page
of 13
Medicine and Science in Sports and Exercise
|
November 5, 2011
Isomaltulose improves glycemia and maintains run performance in type 1 diabetes
Richard Michael Bracken, Rhydian Page, Benjamin Gray, et al.
Kidney International Reports
|
December 19, 2022
Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: <i>post hoc</i> Analysis of the SUSTAIN and PIONEER Programs
David Z I Cherney, Samy Hadjadj, Jack Lawson, et al.
Cardiovascular Diabetology
|
August 24, 2023
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Peter Rossing, Stephen C Bain, Heidrun Bosch-Traberg, et al.
Journal of Sports Sciences
|
December 15, 2010
A combined insulin reduction and carbohydrate feeding strategy 30 min before running best preserves blood glucose concentration after exercise through improved fuel oxidation in type 1 diabetes mellitus
Daniel J West, Jeffrey W Stephens, Stephen C Bain, et al.
Diabetes, Obesity & Metabolism
|
May 4, 2023
Impact of severe hypoglycaemia requiring hospitalization on mortality in people with type 1 diabetes: A national retrospective observational cohort study
Othmar Moser, James Rafferty, Max L Eckstein, et al.
The New England Journal of Medicine
|
June 25, 2023
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
Julio Rosenstock, Stephen C Bain, Amoolya Gowda, et al.
The Lancet. Diabetes & Endocrinology
|
March 28, 2017
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Vanita R Aroda, Stephen C Bain, Bertrand Cariou, et al.
Frontiers in Public Health
|
January 26, 2021
Improved Nocturnal Glycaemia and Reduced Insulin Use Following Clinical Exercise Trial Participation in Individuals With Type 1 Diabetes
Olivia McCarthy, Rachel Deere, Max L Eckstein, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
September 24, 2021
Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population-based observational retrospective cohort study
Kamlesh Khunti, Christin L Hertz, Lise Lotte N Husemoen, et al.
Cardiovascular Diabetology
|
June 7, 2019
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
Lawrence A Leiter, Stephen C Bain, Irene Hramiak, et al.
Page
of 13